Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$19.72

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $19.72 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $19.72 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $19.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $19.7207/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128731674 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

320 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $37,289.40 12/19/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691495187
Principal investigator 1 SANOFI PASTEUR INC. $1,910.00 12/17/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691627895
Principal investigator 1 Merck Sharp & Dohme Corporation $22,891.80 12/11/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691474041
Principal investigator 1 PFIZER INC. $1,365.65 12/11/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671670535
Principal investigator 1 Merck Sharp & Dohme Corporation $2,599.44 12/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536523
Principal investigator 1 Merck Sharp & Dohme Corporation $387.60 12/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536531
Principal investigator 1 Merck Sharp & Dohme Corporation $2,511.21 12/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691537917
Principal investigator 1 Merck Sharp & Dohme Corporation $230.10 12/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691538467
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691474871
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475173
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475205
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475897
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476295
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476303
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476601
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476962
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691478067
Principal investigator 1 Merck Sharp & Dohme Corporation $21.30 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691478077
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691478087
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539699
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540463
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 12/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691541325
Principal investigator 1 Merck Sharp & Dohme Corporation $74.85 12/06/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691509131
Principal investigator 1 PFIZER INC. $3,004.43 11/28/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671672911
Principal investigator 1 Merck Sharp & Dohme Corporation $41,322.60 11/27/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691508655
Principal investigator 1 Merck Sharp & Dohme Corporation $1,159.02 11/22/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691538283
Principal investigator 1 Merck Sharp & Dohme Corporation $1,408.03 11/22/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691538285
Principal investigator 1 Merck Sharp & Dohme Corporation $209.95 11/22/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691538465
Principal investigator 1 GlaxoSmithKline, LLC. $2,222.10 11/20/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669971081
Principal investigator 1 Merck Sharp & Dohme Corporation $6,991.80 11/13/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691474045
Principal investigator 1 SANOFI PASTEUR INC. $8,014.00 11/12/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691625937
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691474865
Principal investigator 1 Merck Sharp & Dohme Corporation $121.00 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475209
Principal investigator 1 Merck Sharp & Dohme Corporation $4.80 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475531
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475887
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475895
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475901
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475981
Principal investigator 1 Merck Sharp & Dohme Corporation $16.16 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476901
Principal investigator 1 Merck Sharp & Dohme Corporation $16.72 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691477257
Principal investigator 1 Merck Sharp & Dohme Corporation $19.36 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691477259
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691477693
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691478083
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479529
Principal investigator 1 Merck Sharp & Dohme Corporation $264.15 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691493959
Principal investigator 1 Merck Sharp & Dohme Corporation $264.15 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691506221
Principal investigator 1 Merck Sharp & Dohme Corporation $29.92 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691520691
Principal investigator 1 Merck Sharp & Dohme Corporation $7.04 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539701
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540655
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691541321
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 11/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691541489
Principal investigator 1 Merck Sharp & Dohme Corporation $465.00 11/05/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691515823
Principal investigator 1 Merck Sharp & Dohme Corporation $16,137.60 11/04/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691473677
Principal investigator 1 Merck Sharp & Dohme Corporation $2,491.13 10/31/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536405
Principal investigator 1 Merck Sharp & Dohme Corporation $260.78 10/31/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536525
Principal investigator 1 Merck Sharp & Dohme Corporation $371.45 10/31/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536529
Principal investigator 1 Merck Sharp & Dohme Corporation $1,931.70 10/31/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691538287
Principal investigator 1 Merck Sharp & Dohme Corporation $12,823.80 10/29/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691442803
Principal investigator 1 PFIZER INC. $6,308.94 10/23/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671669303
Principal investigator 1 Merck Sharp & Dohme Corporation $7,593.60 10/17/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691417099
Principal investigator 1 Merck Sharp & Dohme Corporation $14,207.40 10/11/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449309
Principal investigator 1 Merck Sharp & Dohme Corporation $363.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691474855
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691474861
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475169
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475197
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475201
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475211
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475891
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691475975
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476299
Principal investigator 1 Merck Sharp & Dohme Corporation $1.80 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476591
Principal investigator 1 Merck Sharp & Dohme Corporation $100.80 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476593
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476597
Principal investigator 1 Merck Sharp & Dohme Corporation $2.10 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691477263
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691478073
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691478399
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479135
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479139
Principal investigator 1 Merck Sharp & Dohme Corporation $297.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479181
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479184
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479535
Principal investigator 1 Merck Sharp & Dohme Corporation $131.78 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691479923
Principal investigator 1 Merck Sharp & Dohme Corporation $2,124.87 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691515493
Principal investigator 1 Merck Sharp & Dohme Corporation $337.48 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691515503
Principal investigator 1 Merck Sharp & Dohme Corporation $2,382.82 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536403
Principal investigator 1 Merck Sharp & Dohme Corporation $355.30 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691536527
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691538875
Principal investigator 1 Merck Sharp & Dohme Corporation $792.00 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539871
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540115
Principal investigator 1 Merck Sharp & Dohme Corporation $3.90 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540485
Principal investigator 1 Merck Sharp & Dohme Corporation $82.50 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540745
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540747
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 10/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540975
Principal investigator 1 SANOFI PASTEUR INC. $10,776.00 10/03/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691623451
Principal investigator 1 GlaxoSmithKline, LLC. $2,361.60 10/02/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669965129
Principal investigator 1 GlaxoSmithKline, LLC. $10,714.20 09/30/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
ROTA-090 No dispute reported 06/30/2026 669962585
Principal investigator 1 Merck Sharp & Dohme Corporation $264.15 09/26/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691332792
Principal investigator 1 PFIZER INC. $9,567.15 09/25/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671675163
Principal investigator 1 Merck Sharp & Dohme Corporation $7,842.00 09/20/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691405875
Principal investigator 1 Merck Sharp & Dohme Corporation $17,107.20 09/18/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691406011
Principal investigator 1 Merck Sharp & Dohme Corporation $61.36 09/11/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691416897
Principal investigator 1 Merck Sharp & Dohme Corporation $1,083.10 09/11/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418199
Principal investigator 1 Merck Sharp & Dohme Corporation $1,352.19 09/11/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418367
Principal investigator 1 Merck Sharp & Dohme Corporation $161.50 09/11/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691419781
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449911
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450241
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450371
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450534
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450673
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451173
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452073
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452159
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452169
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452781
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691458585
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 09/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459381
Principal investigator 1 SANOFI PASTEUR INC. $10,660.00 09/10/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691623413
Principal investigator 1 Merck Sharp & Dohme Corporation $4,500.60 09/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691405869
Principal investigator 1 Merck Sharp & Dohme Corporation $16,134.00 09/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691406007
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/27/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691332209
Principal investigator 1 Merck Sharp & Dohme Corporation $17,518.20 08/21/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691406687
Principal investigator 1 Merck Sharp & Dohme Corporation $38,923.20 08/21/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691406691
Principal investigator 1 PFIZER INC. $10,398.09 08/21/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671670363
Principal investigator 1 Merck Sharp & Dohme Corporation $9,376.40 08/20/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691333877
Principal investigator 1 GlaxoSmithKline, LLC. $11,340.10 08/13/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
RSV PED-011 No dispute reported 06/30/2026 669973329
Principal investigator 1 Merck Sharp & Dohme Corporation $1,159.02 08/09/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418207
Principal investigator 1 Merck Sharp & Dohme Corporation $1,191.41 08/09/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418213
Principal investigator 1 Merck Sharp & Dohme Corporation $153.40 08/09/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418371
Principal investigator 1 Merck Sharp & Dohme Corporation $177.65 08/09/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691419787
Principal investigator 1 Merck Sharp & Dohme Corporation $13,266.60 08/09/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691454277
Principal investigator 1 Merck Sharp & Dohme Corporation $21.30 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449713
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449855
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449907
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450021
Principal investigator 1 Merck Sharp & Dohme Corporation $26.40 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450221
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450233
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450237
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450245
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450297
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450365
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450379
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450393
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450479
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450527
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450529
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450567
Principal investigator 1 Merck Sharp & Dohme Corporation $61.84 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450679
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450687
Principal investigator 1 Merck Sharp & Dohme Corporation $6.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451155
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451165
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451169
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451177
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451679
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452067
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452083
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452265
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452929
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452939
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453427
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453551
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453557
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453561
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691458519
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691458525
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691458595
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459219
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459233
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459317
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691461487
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691461493
Principal investigator 1 Merck Sharp & Dohme Corporation $131.78 08/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691461499
Principal investigator 1 SANOFI PASTEUR INC. $10,560.00 08/06/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691622533
Principal investigator 1 Merck Sharp & Dohme Corporation $59.88 08/01/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691362093
Principal investigator 1 PFIZER INC. $9,490.24 07/24/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671635521
Principal investigator 1 Merck Sharp & Dohme Corporation $227.55 07/22/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691343795
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 07/18/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691496711
Principal investigator 1 Merck Sharp & Dohme Corporation $433.24 07/17/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691416391
Principal investigator 1 Merck Sharp & Dohme Corporation $64.60 07/17/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691416901
Principal investigator 1 Merck Sharp & Dohme Corporation $92.04 07/17/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418303
Principal investigator 1 GlaxoSmithKline, LLC. $8,170.70 07/10/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
ROTA-081 No dispute reported 06/30/2026 669962583
Principal investigator 1 Merck Sharp & Dohme Corporation $21.30 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449711
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450227
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450375
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450395
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450399
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450601
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450683
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450693
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451159
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452077
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452163
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452173
Principal investigator 1 Merck Sharp & Dohme Corporation $35.20 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452261
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452271
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452967
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452977
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453637
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453989
Principal investigator 1 Merck Sharp & Dohme Corporation $46,237.80 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691455399
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691458517
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691458589
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459213
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459225
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691459231
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 07/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691461503
Principal investigator 1 SANOFI PASTEUR INC. $12,570.00 07/09/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691624676
Principal investigator 1 Merck Sharp & Dohme Corporation $386.34 07/03/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691416387
Principal investigator 1 Merck Sharp & Dohme Corporation $433.24 07/03/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691416893
Principal investigator 1 Merck Sharp & Dohme Corporation $64.60 07/03/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691416903
Principal investigator 1 Merck Sharp & Dohme Corporation $30.68 07/03/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691419791
Principal investigator 1 PFIZER INC. $15,460.45 06/26/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671635523
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.80 06/12/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669968129
Principal investigator 1 Merck Sharp & Dohme Corporation $82.50 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389849
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389855
Principal investigator 1 Merck Sharp & Dohme Corporation $3.90 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389863
Principal investigator 1 Merck Sharp & Dohme Corporation $2.10 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389973
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390263
Principal investigator 1 Merck Sharp & Dohme Corporation $363.00 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390298
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390383
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390711
Principal investigator 1 Merck Sharp & Dohme Corporation $100.80 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390977
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391043
Principal investigator 1 Merck Sharp & Dohme Corporation $792.00 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391565
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391857
Principal investigator 1 Merck Sharp & Dohme Corporation $1.80 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396727
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397437
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397743
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 06/10/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691398659
Principal investigator 1 Merck Sharp & Dohme Corporation $22,857.60 06/07/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691353971
Principal investigator 1 Merck Sharp & Dohme Corporation $107.38 06/07/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418195
Principal investigator 1 Merck Sharp & Dohme Corporation $113.05 06/07/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418203
Principal investigator 1 Merck Sharp & Dohme Corporation $1,352.19 06/07/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418217
Principal investigator 1 Merck Sharp & Dohme Corporation $758.17 06/07/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691418299
Principal investigator 1 Merck Sharp & Dohme Corporation $223.20 06/06/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691484211
Principal investigator 1 SANOFI PASTEUR INC. $8,040.00 06/04/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691620417
Principal investigator 1 Merck Sharp & Dohme Corporation $199.60 05/29/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691369663
Principal investigator 1 Merck Sharp & Dohme Corporation $443.80 05/24/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691369733
Principal investigator 1 Merck Sharp & Dohme Corporation $1,373.40 05/22/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691313301
Principal investigator 1 PFIZER INC. $13,479.38 05/22/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671641653
Principal investigator 1 GlaxoSmithKline, LLC. $1,354.50 05/15/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669955885
Principal investigator 1 Merck Sharp & Dohme Corporation $11,113.80 05/13/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691313299
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389435
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389441
Principal investigator 1 Merck Sharp & Dohme Corporation $3.60 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389783
Principal investigator 1 Merck Sharp & Dohme Corporation $3.60 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389785
Principal investigator 1 Merck Sharp & Dohme Corporation $363.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389789
Principal investigator 1 Merck Sharp & Dohme Corporation $82.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389845
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389853
Principal investigator 1 Merck Sharp & Dohme Corporation $3.90 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389859
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389921
Principal investigator 1 Merck Sharp & Dohme Corporation $2.10 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389969
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390233
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390235
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390257
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390279
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390301
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390306
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390331
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390353
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390413
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390439
Principal investigator 1 Merck Sharp & Dohme Corporation $100.80 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390715
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390720
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390981
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390991
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390995
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391001
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391039
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391045
Principal investigator 1 Merck Sharp & Dohme Corporation $61.84 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391049
Principal investigator 1 Merck Sharp & Dohme Corporation $8.80 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391059
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391421
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391423
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391495
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391497
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391561
Principal investigator 1 Merck Sharp & Dohme Corporation $297.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391814
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391851
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391853
Principal investigator 1 Merck Sharp & Dohme Corporation $6.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391868
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391879
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396351
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396355
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396875
Principal investigator 1 Merck Sharp & Dohme Corporation $21.30 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397059
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397431
Principal investigator 1 Merck Sharp & Dohme Corporation $792.00 05/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397463
Principal investigator 1 Merck Sharp & Dohme Corporation $1,266.00 05/07/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691366385
Principal investigator 1 Merck Sharp & Dohme Corporation $147.75 05/07/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691369653
Principal investigator 1 SANOFI PASTEUR INC. $12,060.00 05/07/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618951
Principal investigator 1 Merck Sharp & Dohme Corporation $3,000.00 05/02/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691369657
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/02/2019 Non-covered Recipient Entity
SENDERS SHELLY D MD
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691369661
Principal investigator 1 Merck Sharp & Dohme Corporation $17,057.40 04/26/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691325479
Principal investigator 1 PFIZER INC. $6,574.32 04/17/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671641655
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 04/12/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691313921
Principal investigator 1 Merck Sharp & Dohme Corporation $4,500.60 04/12/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691314055
Principal investigator 1 SANOFI PASTEUR INC. $13,770.00 04/09/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691619149
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 04/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390275
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 04/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391427
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 04/08/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391499
Principal investigator 1 Merck Sharp & Dohme Corporation $3,968.40 04/05/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691314053
Principal investigator 1 GlaxoSmithKline, LLC. $1,692.90 04/03/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669971787
Principal investigator 1 Merck Sharp & Dohme Corporation $8,683.20 04/03/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691324545
Principal investigator 1 Merck Sharp & Dohme Corporation $1,704.00 03/19/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691319271
Principal investigator 1 GlaxoSmithKline, LLC. $1,179.00 03/14/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669956787
Principal investigator 1 GlaxoSmithKline, LLC. $1,654.20 03/14/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669971771
Principal investigator 1 Merck Sharp & Dohme Corporation $27,438.60 03/13/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691314051
Principal investigator 1 PFIZER INC. $10,078.97 03/13/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671630575
Principal investigator 1 SANOFI PASTEUR INC. $8,040.00 03/07/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618625
Principal investigator 1 Merck Sharp & Dohme Corporation $2,044.80 02/28/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691319273
Principal investigator 1 SANOFI PASTEUR INC. $7,740.00 02/14/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691620291
Principal investigator 1 Merck Sharp & Dohme Corporation $124.75 02/13/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691344691
Principal investigator 1 PFIZER INC. $16,326.48 02/04/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671617785
Principal investigator 1 PFIZER INC. $11,066.38 02/04/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 671617787
Principal investigator 1 Merck Sharp & Dohme Corporation $340.80 01/29/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691312133
Principal investigator 1 Merck Sharp & Dohme Corporation $2,470.58 01/28/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391417
Principal investigator 1 GlaxoSmithKline, LLC. $1,952.10 01/24/2019 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669953295
Principal investigator 1 Merck Sharp & Dohme Corporation $33,070.20 01/24/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691307531
Principal investigator 1 Merck Sharp & Dohme Corporation $4,820.40 01/17/2019 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691311481
Principal investigator 1 SANOFI PASTEUR INC. $5,475.00 01/10/2019 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691617989